News and Events News Algok Bio Enters into Exclusive Worldwide License Agreement with BTG to Develop and Commercialize Idetrexed, a Clinical-Stage Folate Receptor-Targeted Oncology Drug April 11, 2023 News Algok Bio Acquires Global Rights to a First-In-Class Antibody Therapeutic Candidate Targeting TM4SF4 from KAERI December 14, 2021 Load More News and Events
